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A B S T R A C T
Developmentally-lead (Pb)-exposed rats showed an enhanced vulnerability to the stimulating and motivational
effects of ethanol (EtOH). This is accompanied by differential activity of the brain EtOH-metabolizing enzymes
catalase (CAT) and mitochondrial aldehyde dehydrogenase (ALDH2). Based on the theory that brain acet-
aldehyde accumulation is associated with the reinforcing properties of EtOH, this study sought to determine
brain CAT and ALDH2 expression in limbic areas of control and Pb-exposed animals after voluntary EtOH intake.
Thirty-five-day-old rats perinatally exposed to 220 ppm Pb were offered with water or increasing EtOH solutions
(2–10% v/v) during 28 days until postnatal day (PND) 63. Once intake was stable, the animals were adminis-
tered: 1) saline (SAL; test days 21–24 or 21–28, as corresponds), or 2) a CAT inhibitor: 3-amine 1, 2, 4-triazole
(AT; 250mg/kg intraperitoneally [i.p.], 5 h before the last eight EtOH intake sessions -test days 21–24 and
25–28), or 3) a CAT booster: 3-nitropropionic acid (3NPA; 20mg/kg subcutaneously [s.c.], 45min before the last
four EtOH intake sessions -test days 25–28). Two additional groups were centrally-administered cyanamide (CY,
an ALDH2 inhibitor, 0.3 mg i.c.v. immediately before the last four EtOH sessions, test days 25–28) or its cor-
responding vehicle (VEH). Lead exposure increased EtOH intake, an effect potentiated in both groups by 3NPA
or CY pretreatments and reduced by AT, albeit selectivity in the Pb group. Catalase abundance in limbic areas
parallels these observations in the Pb group, showing higher CAT expression in all areas after EtOH consumption
respect to the controls, an effect prevented by AT administration. In contrast, ALDH2 expression was reduced in
the Pb animals after EtOH intake, with CY potentiating this effect in all brain areas under study. Based on these
results and on previous evidences, we suggest that Pb exposure promotes acetaldehyde accumulation in limbic
regions, providing some insights into the mechanism of action that underlies the vulnerability to the excessive
EtOH consumption reported in these animals.
1. Introduction
The developmental neurotoxicant lead (Pb) is a non-essential metal
that has been extensively used in the past. Although several industrial
applications have been banned or restricted, neurobehavioral altera-
tions are still reported in environmentally-Pb-exposed children.
Experimental evidences in rodents indicate an enhanced vulnerability
to the stimulating and motivational effects of ethanol (EtOH) as result
of Pb exposure (Nation et al., 1986; Correa et al., 1999a; Virgolini et al.,
2017). Since brain acetaldehyde accumulation is considered a key
component of these responses (Aragon and Amit, 1985; Quertemont
et al., 2005; Israel et al., 2015), EtOH metabolism emerged as an im-
portant aspect to consider when evaluating the mechanism that un-
derlies the Pb-EtOH interaction.
Catalase (CAT) is an antioxidant enzyme that represents the major
metabolic pathway of brain EtOH oxidation to acetaldehyde. This
process requires H2O2 as a co-factor (Cohen et al., 1980; Aragon et al.,
1992; Zimatkin and Buben, 2007), and plays a key role in EtOH phar-
macological effects (Quertemont et al., 2005; Correa et al., 2012; Peana
et al., 2017). Pb itself increases both, CAT activity and several EtOH
responses when administered either acutely to adult animals (Correa
et al., 1999b), or chronically to developmental rats (Valenzuela et al.,
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1989; Mattalloni et al., 2013) or chickens (Somashekaraiah et al.,
1992). Interestingly, we have demonstrated that pharmacological
(Mattalloni et al., 2013) or molecular (Mattalloni et al., 2019) manip-
ulations of this enzyme have a direct impact on CAT activity and vo-
luntary EtOH intake in developmentally Pb-exposed rats (reviewed in
Virgolini et al., 2017). Similarly, CAT inhibition with specific antago-
nists such as 3-amino 1,2,4-triazole (AT) or sodium azide reduced both
EtOH-induced locomotor activity (Sanchis-Segura et al., 1999; Correa
et al., 2001) and the drug’s anxiolytic responses (Correa et al., 2008). A
comparable effect emerged when EtOH consumption was evaluated
after pharmacological CAT blockade (Aragon and Amit, 1992; Tampier
et al., 1995; Mattalloni et al., 2013). Moreover, an shRNA antiCAT
vector abolished EtOH intake in the UChB rats, a strain which prefers
EtOH (Karahanian et al., 2011). Conversely, CAT activation with 3-ni-
tropropionic acid (3NPA) enhanced EtOH-induced locomotion
(Manrique et al., 2006) and increased EtOH consumption (Mattalloni
et al., 2013) in rodents.. Regarding its localization, CAT is an enzyme
present in the brain, liver, and kidney, intracellularly in the peroxi-
somes of rats (Moreno et al., 1995; Zimatkin and Lindros, 1996) and
humans (Houdou et al., 1991). Although low compared to liver, brain
CAT expression has been reported in both neurons and glia, with pre-
ferential immunoreactivity in the aminergic system, providing a func-
tional relevance to the presence of the enzyme in the brain (Moreno
et al., 1995; Zimatkin and Lindros, 1996). These evidences contrast
with the low expression of the other two enzymes that participate in
minor pathways of brain EtOH metabolism. They are CYP2E1, which is
localized preferably in cortical, striatal and hippocampal regions
(Hansson et al., 1990) and ADH, present in neurons of the mammillary
bodies, periaqueductal gray, and the cerebral and cerebellar cortices of
normal adult rats (Kerr et al., 1989).
On the other hand, the next step of EtOH metabolism involves brain
(and liver) acetaldehyde oxidation to acetic acid by the ALDH super-
family of enzymes. Of particular interest is the cytosolic ALDH1A1 and
the mitochondrial ALDH2, with the latter having the highest affinity for
acetaldehyde (Km<1 μM) (Zimatkin et al., 2006; Marchitti et al.,
2008). They are ubiquitously distributed in the rat brain, showing ro-
bust immunoreactivity in the extranuclear areas of the neuronal and
glial cell bodies, accompanied by lower staining in the terminals and in
aminergic neurons (Zimatkin et al., 1992). Interestingly, it has been
reported that brain (rather than liver) ALDH2 activity closely correlates
with EtOH preference (Amir, 1977). Moreover, low-doses of centrally-
administered cyanamide (CY), an ALDH antagonist, enhanced sub-
sequent EtOH intake (Critcher and Myers, 1987), and adding further
support to the postulate that brain acetaldehyde is a metabolite in-
volved in the positive reinforcing properties of EtOH (Aragon and Amit,
1985; Quertemont et al., 2005; Israel et al., 2015). In this regard, we
have recently demonstrated that CY increased EtOH intake by reducing
brain mitochondrial ALDH2 activity in rodents when the drug was
administered directly in the brain. Interestingly, basal brain ALDH2
activity was lower in the Pb-exposed animals which had consumed
EtOH compared to their control counterparts (Mattalloni et al., 2017),
suggesting that central acetaldehyde accumulation make these animals
more vulnerable to the development of excessive EtOH intake (re-
viewed in Virgolini et al., 2017).
Thus, on the basis of the critical role ascribed to CAT and ALDH2 in
brain acetaldehyde accumulation, and their differential activity in the
Pb-exposed rats, we aimed here to evaluate brain CAT and ALDH2
expression resulting of EtOH consumption in basal conditions and after
pharmacological modulation of these two enzymes.
2. Material and methods
2.1. Animals and perinatal treatment
Adult male and female Wistar rats born and bred in our vivarium
(IFEC−CONICET, Córdoba, Argentina) housed in a ratio of 1 male/2
females per cage were maintained with a standard diet (Purina chow,
Batistella, Argentina) ad libitum in a 12 h dark/light cycle (lights on at
07:00 a.m.) under constant conditions of temperature and humidity.
They were randomly allocated to one of two subsets according to the
fluid source: control group (designated as C) which received filtered tap
water; or lead group (designated as Pb), offered with a 220 ppm Pb
solution (0.4 g/l lead acetate; Mallinckrodt, J.T. Baker; Argentina). It
should be noted that the tap water contains less than 5.0 μg/l Pb as
indicated by the filter company (Water Systems, Pure Air Technology,
Argentina). Daily fluid intake measurement demonstrates the absence
of differences in liquid consumption as a result of the presence of Pb
acetate in the solution. The dam’s weight was registered once a week to
determine weight gain during pregnancy, and discard any treatment-
related effects in the nutritional status. Within 24 h of delivery (desig-
nated as postnatal day 1: PND1), the number of male and female pups
was counted and litters culled to eight pups, keeping all males when-
ever possible, though one female was always present in each litter. Pups
were weighed once a week until weaning at PND25 when Pb exposure
was interrupted by replacing the Pb solution for filtered tap water as the
only source of beverage. Tests started at PND35, a time considered
periadolescence in rats (Sengupta, 2013), and a highly risky period for
the initiation of drug addiction (Spear, 2000), and continued until early
adulthood at PND63. One male per litter was allocated to each ex-
perimental condition as suggested by Maurissen (2010), except for
EtOH intake tests where 2 pups from the same litter were housed to-
gether and considered a single case. Efforts were made to minimize pain
and suffering and to reduce the number of animals used. All procedures
were in accordance with the NIH Guide for the Care and Use of La-
boratory Animals, as approved by the Animal Care and Use Committee
of the Facultad de Ciencias Químicas (CICUAL), Universidad Nacional
de Córdoba, Argentina (Protocol HCD FCQ-UNC 564/15).
2.2. Ethanol consumption and drug treatment
The day before the start of the EtOH/water free-choice test, a
random subset of 35-day-old male pups (Group PND35) was weighed
and later sacrificed to obtain brain tissue as detailed below. Other
groups of rats of the same age and gender were weighed, housed in
pairs, and water-restricted for the 24 h prior to the initiation of the
EtOH intake protocol. Access to fluids was scheduled to be limited to
2 h per day between 10:00 a.m. and 4:00 p.m. to model “binge
drinking”, which is a more realistic approach of alcohol consumption
patterns in adolescents. Thus, starting on PND35, these animals had
access for 28 days to four graduated tubes containing either water (two
tubes) or escalating concentrations of EtOH (two tubes) according to
the following scheme (expressed in v/v): days 1-4: 2%; days 5-8: 4%;
days 9-12: 6%; days 13-16: 8%; days 17-28: 10% EtOH. This strategy
consisted in the presentation of EtOH at a relatively low concentration
followed by the gradual increase of its content over days to acclimatize
the animals to the naturally aversive taste of the drug. During the whole
test, rats were weighed and both EtOH and water intake registered daily
to be expressed as grams of EtOH per kilogram of body weight.
Once liquid intake was stabilized at the 10% EtOH concentration, a
group of rats were daily injected with 1) saline (SAL; test days 21–24 or
21–28, as corresponds), or 2) a CAT inhibitor: 3-amine 1, 2, 4-triazole
(AT; 250mg/kg dissolved in 0.9% SAL and administered in-
traperitoneally [i.p.], 5 h before the last eight EtOH intake sessions -test
days 21–24 and 25–28), or 3) a CAT booster: 3 nitropropionic acid
(3NPA; 20mg/kg dissolved in 0.9% SAL and administered sub-
cutaneously [s.c.], 45min before the last four EtOH intake sessions -test
days 25–28). The timing, route of administration and dosing of these
drugs were based on available literature (Aragon et al., 1991; Binienda
et al., 1998) and on previous data published by us (Mattalloni et al.,
2013). At the same time, in a fourth group cyanamide (CY, a long-
lasting ALDH2 inhibitor that does not cross the blood-brain-barrier)
was microinfused intracerebroventricularly (i.c.v.) in a dose of 0.3mg
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immediately before the last four EtOH sessions (test days 25–28). This
administration protocol was based in Deitrich et al., 1976 and used by
us in Mattalloni et al., 2017. It should be noted that CY was dissolved in
standard Krebs solution and saturated with 95% O2 and 5% CO2, which
was the solution administered i.c.v. to the fifth group labeled as vehicle
(VEH). To perform the surgery on days 20–21 of the free-choice test,
rats were anesthetized with ketamine hydrochloride (55mg/kg) and
xylazine (11mg/kg) to unilaterally implant a cannula (14mm, 22-
gauge stainless steel) in the lateral ventricle (AP -0.9, ML -1.5, DV -3.6)
with coordinates taken from Paxinos and Watson (2009). After the
animals recovered from the surgery and the EtOH consumption test
resumed, unilateral infusions of the drug delivered by a pump (Harvard
Apparatus model #22, Holliston, MA) were performed daily for the last
four days of the experiment. A representative scheme of the perinatal
treatment, EtOH consumption and drugs administered time-line is
shown in Fig. 1.
Therefore, the experimental groups for each prenatal treatment (C
or Pb) were conformed as follows: PND35, PND63 EtOH-SAL, PND63
EtOH-AT and PND63 EtOH-3NPA for the systemically-injected animals,
and PND63 EtOH-VEH and PND63 EtOH-CY for those centrally-in-
jected. In addition, adult C and Pb-exposed animals of the same age
administered with identical drug schemes, but not subjected to the
EtOH intake protocol were sacrificed concurrently. They conform five
additional groups: PND63 non-EtOH-SAL, PND63 non-EtOH-AT,
PND63 non-EtOH-3NPA, PND63 non-EtOH-VEH, and PND63 non-
EtOH-CY.
2.3. Brain sample collection
At the end of the experiments, all rats were anesthetized with an i.p.
injection of ketamine hydrochloride (55mg/kg) and xylazine (11mg/
kg) and transcardially perfused exposing the thoracic cavity and ob-
structing the blood flux in the descendent aorta. They were first per-
fused with a SAL/heparin solution 0.9% NaCl/1000 units/l (approx.
Fig. 1. Experimental timeline. The figure is a representative sequence of the protocol applied to the group of animals perinatally exposed to Pb (Pb groups) which
underwent the EtOH/water free choice test (EtOH groups) and were later administered one of the drugs under study (AT, 3NPA or CY) to be finally sacrificed. Other
groups not depicted here include the animals not exposed to Pb (C), those which were sacrificed at PND35, those injected with SAL or VEH, and the rats which did not
consume EtOH (non-EtOH groups). GD= gestational day; PND=postnatal day; EtOH= ethanol; C= control; Pb= lead-exposed; SAL= saline; AT=3-amino
1,2,4-triazole; 3NPA=3-nitropropionic acid; VEH=vehicle; CY= cyanamide. Further details are provided in the main text of the manuscript.
Fig. 2. Voluntary ethanol (EtOH) intake expressed as grams of EtOH per kilogram of body weight in response to AT (panel A), 3NPA (panel B) or CY (panel
C) administration. At the top of each graph is depicted the EtOH metabolism after pharmacological manipulations (taken from Quertemont and Didone, 2006). Data
(mean + SE) grouped in 4-day blocks along the horizontal axis correspond to EtOH intake in response to increasing EtOH concentrations (days 1 to 4: 2%; days 5 to
8: 4%; days 9 to 12: 6%; days 13 to 16: 8%; and days 17 to 28: 10% v/v). C= control; Pb= lead-exposed; SAL= saline; AT=3-amino 1,2,4-triazole; 3NPA=3-
nitropropionic acid; VEH=vehicle; CY= cyanamide. n= 5 animals for each group. Panel A: *indicates differences respect to the C animals at ***p<0.001. Panel B:
*indicates differences respect to the C animals at ***p<0.001. Panel C: The symbol indicates the time of surgery. *indicates differences respect to the C animals at
***p < 0.001. Once VEH or CY was administered: *indicates significant differences between the C-VEH and Pb-VEH animals at *p<0.05 and #indicates significant
differences between the C-VEH and C-CY-treated animals at ##p<0.01.
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250ml/rat) and later with 4% paraformaldehyde fixing solution in
phosphate buffer (PB) 0.1M pH=7.4 (approximately 300–350ml/rat).
Brains were removed and kept on the 4% paraformaldehyde solution
for 12 h at 4 °C to be later placed in a 30% sucrose in PB solution for
72 h at 4 °C until analysis.
The day of the experiment the brains were quickly frozen with an
aerosol (Biofreeze, Biopack) and glued to the cryostat with a cryopro-
tector medium (Cryoplast, Biopack). To make the temperature uniform
between the tissue and the mounting medium, the samples were left for
15–20min before sectioned in 30 μm thick slices by the use of a cryostat
(Leica CM15105). Sections from the nucleus accumbens (NAc), dorsal
striatum (dStr), and prefrontal cortex (PFC) were obtained according to
Paxinos and Watson (2009). The slices were washed with 0.01 PB three
times for 10-min intervals and later incubated with 10% methanol, 30%
H2O2 in PB for 1 h in a shaker to eliminate the endogenous peroxidase.
Afterward, three 10-min washes were made with 0.01 PB and the sec-
tions incubated for 2 h under constant orbital agitation. This step in-
cluded a blocking solution containing 1% bovine serum albumin (BSA
Tethaedron), 0.1% Triton X-100, 10% goat serum or 10% normal horse
serum (Sigma, Argentina) for CAT or ALDH2 respectively, in 0.01M
PBS in order to block unspecific antibody bindings. The sections were
then incubated overnight at 4 °C in agitation with a rabbit polyclonal
anti-CAT antibody (1:1500, Abcam) or a mouse monoclonal antiALDH2
antibody (1:1000, Abcam). The sections were then washed three times
Fig. 3. Body weights of C and Pb-exposed animals which consumed EtOH (left panels) and their non-EtOH counterparts (right panels). All measurements
were recorded weekly during 4 weeks (days 1–28 of the free-choice test). The number of animals corresponds to n= 10 per group for the animals which consumed
EtOH and n=3–5 for their non-EtOH counterparts. EtOH= ethanol; C= control; Pb= lead-exposed; SAL= saline; AT=3-amino 1,2,4-triazole; 3NPA=3-ni-
tropropionic acid; VEH=vehicle; CY= cyanamide.
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for 10min and incubated for 2 h in a shaker with a biotinylated sec-
ondary antibody (anti-rabbit 1:1000, Vector Laboratories, Burlingame,
CA, USA or anti-mouse, 1:2000, Jackson Immunoresearch, as appro-
priate). This was followed by the incubation with the avidin-biotin-
peroxidase complex (Vector ABC kit, Burlingame, CA, USA) for 1 h at
room temperature. Diamine benzidine (DAB, Sigma Aldrich, Argentina)
as a chromogenic was used for 5–7min in a solution containing 0.05%
DAB and 0.006% H2O2 in 0.1M PB. The final product developed a
brownish coloration in the presence of the enzyme of interest, labeling
with no coloration in the negative control. Once finished, three 10-min
washes were made with 0.1M PB. The slices were later mounted in
glasses with a solution conformed by 1.5% gel and 80% alcohol and
once dried, cover with mounting solution (DPX, Sigma, Argentina) and
coverslip for visualization. In the case of CAT, to unmask the antigenic
epitopes, the HIER (heat induced epitope retrieval) technique was
employed before the immunohistochemistry protocol (Cholich et al.,
2008).
Catalase and ALDH2 positive cells quantification: A light field micro-
scope (Leica DM 4000B, Cambridge, UK) with a mounted camera (Leica
DFC 300Fx) and the IM50 (Leica) software with a 20x magnification
was used to count CAT positive cells, while 40x magnification was used
for ALDH2 quantification. Two slices of each brain region (4 fields of
each area) were selected and both hemispheres quantified to obtain a
final count average for each experimental group with the aid of the
software IMAGE J (National Institutes of Health, NIH, US).
2.4. Statistical analysis
To facilitate analysis, daily EtOH intake data were collapsed into the
four days corresponding to the same EtOH concentration. Thus, the
average for the 2%, 4%, 6%, 8% and the 10% EtOH concentrations
(days 1–20) were analyzed by a two-way repeated measure analysis of
variance (ANOVA), contrasting the group (C vs. Pb) against the time/
EtOH concentration as the repeated variable. Once the AT administra-
tion protocol was implemented (test days 21–24 and 25–28), data were
analyzed by a three-way-repeated-measures ANOVA by comparisons
between group (C vs. Pb), drug (SAL vs. AT) and time/EtOH con-
centration as the repeated variable. In the case of 3NPA or CY (days
25–28), a two-way ANOVA was applied, with the group (C vs. Pb) and
drug (SAL vs. 3NPA or VEH vs. CY, as appropriate) and time/EtOH
concentration as the variables to contrast. In all cases, when significant
interactions were found, a Tukey´s test was performed as a post hoc
analysis, with resulting p values indicated in the corresponding figure
legends.
To avoid large data comparison, body weights values were analyzed
in a separate analysis for each EtOH condition by contrasting the group
and the drug parameters and time as the repeated variable.
In relation to the immunohistochemical data, the analysis of each
brain region was evaluated separately. On one hand, the effect of
postnatal age on the enzymes’ expression was analyzed by a two-way
ANOVA contrasting group (C vs. Pb) and age/EtOH condition (groups
PND35, PND63 EtOH, and PND63 non-EtOH). In addition, to evaluate
the effects of the drugs on each enzyme expression a separated group of
Fig. 4. CAT expression in the nucleus accumbens (NAc) in basal conditions and after drug administration. Panels A & D: Cell count (A) and representative
pictures (D) of 35-day-old rats. Panels B & E: Cell count (B) and representative pictures (E) of 63-day-old rats which had consumed EtOH. Panels C & F: Cell
count (C) and representative pictures (F) of 63-day-old rats which had not consumed EtOH. The data represent the results of 4 animals per group.
PND=postnatal day; EtOH= ethanol; C= control; Pb= lead-exposed; SAL= saline; AT=3-amino 1,2,4-triazole; 3NPA=3-nitropropionic acid.
Panel A: &denotes significant differences respect to the PND63 non-EtOH animals from the same group (C or Pb) at &&p < 0.01. Panels B & C: *indicates significant
differences respect to the C animals from the same drug (SAL, AT or 3NPA) and EtOH (EtOH or non-EtOH) conditions at ***p < 0.001; #denotes significant
differences between the SAL and AT-pretreated animals from the same group and EtOH conditions at ###p < 0.001; ^indicates significant differences between the
SAL and 3NPA-treated animals from the same group and EtOH conditions at ^^^p < 0.001; $denotes significant differences respect to their respective EtOH coun-
terparts from the same group and drug conditions at $$$p < 0.001.
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data was analyzed by a three-way ANOVA (group x drug x EtOH con-
dition) followed by a Tukey´s test as a post hoc analysis. It should be
noted that although shown in separated figures, the EtOH and non-
EtOH animals were analyzed together to contrast the effect of EtOH
intake on each enzyme expression.
3. Results
3.1. Ethanol intake
Fig. 2 represents total EtOH consumption of escalating solutions
(2–10% EtOH v/v) in basal conditions and in response to AT (panel A),
3NPA (panel B) or CY (panel C) administration. It should be noted that
this data corresponds to a large group of animals that include the subset
sacrificed for the immunohistochemistry assays described below. Thus,
replicating previous results, (Mattalloni et al., 2013, 2017 & 2019) Pb-
exposed rats increased their EtOH intake over time, which became re-
latively stable after the 6% EtOH concentration. In contrast, C animals
demonstrated a steady low EtOH intake over the length of the experi-
ment. The statistical analysis performed for each drug condition is de-
tailed in the corresponding section.
3.1.1. Effect of AT administration
Starting on test day 21 (Fig. 2A), when EtOH intake was stabilized
and showed to be significantly higher in the Pb-exposed rats (group
effect: F(172)= 34.71, p < 0.001), CAT inhibition was in effect (as
indicated by the two arrows on days 21–24 and 25–28). The results
show that AT pretreatment abolished the elevated EtOH consumption
observed in the Pb-exposed animals reaching similar values than their
corresponding SAL-treated counterparts, while such an effect was not
evident in the C animals. In support of this conclusion, a three-way-
repeated-measures ANOVA indicated a significant effect in the group: F
(116) = 24.69, p < 0.001 and in the drug: F(116) = 4.62, p < 0.05
variables, but no overall interaction was evident.
3.1.2. Effects of 3NPA administration
Baseline data plotted in Fig. 2 (panel B) shows a significant effect of
the group: F(190)= 63.25, p < 0.001, and the time/EtOH con-
centration: F(590)= 52.23, p < 0.001 variables, as well as a sig-
nificant interaction between both parameters: F(590)= 2.64,
p < 0.05. The arrow indicates the start of 3NPA administration (test
days 25–28) which promoted an increase in EtOH intake in both, the C
and Pb-exposed animals compared to the respective SAL-injected rats.
These differences were evidenced by the two-way ANOVA results re-
vealing a significant effect in the group: F(116)= 41.14, p < 0.001,
and drug: F(116) = 13.04, p < 0.01 variables, but not in their in-
teraction.
3.1.3. Effect of CY administration
The data plotted in Fig. 2 (panel C) in basal conditions shows a
significant effect of the group variable: F(190)= 21.39, p < 0.001,
and of the time/EtOH concentration repeated variable: F(590)= 15.25,
p < 0.001, but no interaction emerged between both parameters. In-
terestingly, CY administration (indicated by an arrow in test days
Fig. 5. CAT expression in the dorsal striatum (dStr) in basal conditions and after drug administration. Panels A & D: Cell count (A) and representative
pictures (D) of 35-day-old rats. Panels B & E: Cell count (B) and representative pictures (E) of 63-day-old rats which had consumed EtOH. Panels C & F: Cell
count (C) and representative pictures (F) of 63-day-old rats which had not consumed EtOH. The data represent the results of 4 animals per group.
PND=postnatal day; EtOH= ethanol; C= control; Pb= lead-exposed; SAL= saline; AT=3-amino 1,2,4-triazole; 3NPA=3-nitropropionic acid.
Panel A: ˜indicates significant differences respect to the PND63 EtOH animals from the same group (C or Pb) at ˜˜p < 0.01; &denotes significant differences respect to
the PND63 non-EtOH animals from the same group at &&p < 0.01. Panels B & C: *indicates significant differences respect to the C animals from the same drug (SAL,
AT or 3NPA) and EtOH (EtOH or non-EtOH) conditions at ***p < 0.001; #denotes significant differences between the SAL and AT-pretreated animals from the same
group and EtOH conditions at ###p < 0.001; $denotes significant differences respect to their respective EtOH counterparts in the same group and drug conditions at
$$$p < 0.001.
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25–28) elicited a significant increase in EtOH consumption, an effect
evidenced in both groups as a result of brain ALDH inhibition. This was
statistically supported by the significant difference that emerged both in
the group: F(116)= 8.29, p < 0.05, in the drug: F(116)= 13,32,
p < 0.01 variables, and in their interaction F(116) = 4.62, p < 0.05.
Individual comparisons are denoted in the figure and detailed in the
respective legend.
3.2. Body weights
Fig. 3 depicts body weights of the animals assessed in the EtOH free-
choice test (lefts panels) and of their non-EtOH counterparts (rights
panels). From the observation of the figure it is evident that all animals
have similar weights at PND35 (the start of the free choice test) as noted
in the points of the curves that intersect the y axis. The figure also
shows that EtOH intake and most probably the 2-h-restricted access to
fluids prevented the animals to reach the same weight than the non-
EtOH group. In addition, the brain surgery performed on week 3 to
implant the canula for i.c.v. administrations had minor impact on
weight gain in both, C and Pb-exposed rats independently of the EtOH
condition. The statistical analysis shows the absence of group or drug
effects in the animals which consumed EtOH, albeit a significant effect
in the time/EtOH concentration (F(3162)= 216.32, p < 0.001) was
evident. Similar results were obtained when body weight of the non-
EtOH animals was analyzed, with a significant difference present only
in the repeated variable time (F(387)= 1244.40, p < 0.001). Overall,
these results indicate normal curves of weight gain of the animals
evaluated in this study, which suggest a good health status with and
minor disturbances resulting of the treatments applied.
3.3. Immunohistochemical studies
3.3.1. CAT expression
CAT expression in the NAc, dStr and PFC brain regions of 35-day-old
animals is shown in panel A of Figs. 4–6, with a representative picture
of each brain area shown in Panel D of the corresponding figure. In
addition, panels B and C depict CAT expression in the 63-day-old ani-
mals after EtOH intake (Panel B) or in their non-EtOH counterparts
(Panel C). Representative pictures of the corresponding brain area and
drug administered are shown in Panels E and F, respectively.
3.3.1.1. Effect of age and EtOH intake on brain CAT expression. The two-
way ANOVA performed for each region separately shows that in the
NAc (Fig. 4A and SAL-bars of panels B & C), a significant effect of group:
F(1,18)= 72.80; p < 0.001, and age/EtOH intake: F(2,18)= 120.75;
p < 0.001 was found, with no interaction between them. This analysis
demonstrates a higher abundance of the enzyme in the Pb-exposed
animals independently of the age and EtOH intake. A different effect
was observed in the dStr (Fig. 5A and SAL-bars of panels B and C) where
a significant effect of group: F(1,18)= 22.03; p < 0.001, age/EtOH
intake: F(1,18)= 7.38; p < 0.01, and of the interaction between them:
F(2,18)= 5.08; p < 0.05 was observed. These results indicate that the
Fig. 6. CAT expression in the prefrontal cortex (PFC) in basal conditions and after drug administration. Panels A & D: Cell count (A) and representative
pictures (D) of 35-day-old rats. Panels B & E: Cell count (B) and representative pictures (E) of 63-day-old rats which had consumed EtOH. Panels C & F: Cell
count (C) and representative pictures (F) of 63-day-old rats which had not consumed EtOH. The data represent the results of 4 animals per group.
PND=postnatal day; EtOH= ethanol; C= control; Pb= lead-exposed; SAL= saline; AT=3-amino 1,2,4-triazole; 3NPA=3-nitropropionic acid.
Panel A: *indicates significant differences respect to the C animals of the same age at ***p < 0.001; ˜indicates significant differences respect to the PND63 EtOH
animals from the same group (C or Pb) at ˜˜p < 0.01; &denotes significant differences respect to PND63 non-EtOH from the same group (C or Pb) at &&&p < 0.001.
Panels B & C: *indicates significant differences respect to the C animals in the same drug (SAL, AT or 3NPA) and EtOH (EtOH or non-EtOH) conditions at *p < 0.05
and ***p < 0.001; #denotes significant differences between the SAL and AT-pretreated animals from the same group and EtOH conditions at ###p < 0.001;
^indicates significant differences between the SAL and 3NPA-treated animals from the same group and EtOH conditions at ^^^p < 0.001; $denotes significant
differences respect to their respective EtOH counterparts in the same group and drug conditions at $$$p < 0.001.
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enzyme show a higher expression selectively in the Pb-exposed rats
only after voluntary EtOH consumption. On the other hand, in the PFC
(Fig. 6A and SAL-bars of panels B and C) there was a significant effect of
group: F(1,18)= 34.75; p < 0.001, and of age/EtOH intake F
(2,18)= 27,55; p < 0,001, as well as in the interaction between
them: F(2,18)= 37.26; p < 0.001. Thereby, a higher CAT expression
was present in the Pb-exposed animals at young age, an effect that
persisted only after EtOH intake.
3.3.1.2. Effect of drug (SAL, AT or 3NPA) pretreatment on brain CAT
expression. The three-way ANOVA performed for each area shows that
in the NAc (Fig. 4B and C), a significant difference was observed in the
group: F(1,36)= 9.70; p < 0.05, EtOH intake: F(1,36)= 5.98;
p < 0.05, and drug: F(2,36)= 110.71; p < 0.001 variables. This
was also evident in the interactions between group x drug: F
(2,36)= 47.97; p < 0.001, EtOH intake x drug: F(2,36)= 56.21;
p<0.001, group x EtOH intake: F(1,36)= 8.85; p < 0.01, and drug
x group x EtOH intake: F(2,36)= 4.61; p < 0.05. These results
demonstrate a reduction in CAT expression in this area in both, C and
Pb-exposed rats after EtOH intake as a consequence of AT
administration. However, in non-EtOH conditions this effect was only
evident in the Pb-exposed group. On the other hand, 3NPA
administered at the end of the EtOH intake protocol failed to change
basal CAT expression in both C and Pb-exposed rats. This result contrast
with the significant increase in CAT expression observed in both groups
in a non-EtOH condition. In the dStr (Fig. 5B and C) the analysis shows
a significant difference in the group: F(1,36)= 21.43; p < 0,001 and
drug: F(2,36)= 22.19; p < 0.001 variables, and in their interaction: F
(2,36)= 10.11; p < 0.001. In the same line, differences emerged in the
group x EtOH intake: F(1,36)= 9.05; p < 0.005, EtOH intake x drug: F
(2,36)= 20.47; p < 0.001 and in the group x drug x EtOH intake
overall interaction: F(2,36)= 6.67; p < 0.01. These differences were
evidenced as a significant reduction in CAT expression selectively in the
Pb-exposed group after voluntary EtOH intake as a consequence of AT
administration. Conversely, 3NPA reproduced the CAT expression
observed in the SAL-injected animals in both groups and EtOH
conditions. In the PFC (Fig. 6B and C) there was a significant effect in
the drug variable: F(2,36)= 29.45; p < 0.001, as well as of the group
x EtOH intake: F(1,36)= 6.30; p < 0.05, group x drug: F
(2,36)= 3.27; p < 0.05, drug x EtOH intake: F(2,36)= 12.85;
p < 0.001 interactions, and of the group x drug x EtOH intake: F
(2,36)= 10.71; p < 0.001 overall interaction. These results
demonstrated that AT reduced CAT expression selectively in the Pb-
exposed rats after EtOH intake, whereas 3NPA blunted the differences
observed between the SAL-injected C and Pb-exposed animals in both
the EtOH and non-EtOH conditions.
3.3.2. ALDH expression
Figs. 7–9 (panel A) represent ALDH2 expression in the NAc, dStr,
and PFC, respectively in 35-day-old animals with a representative pic-
ture shown in Panel D of each figure. Panels B and C depict ALDH2
expression of the 63-day-old animals after EtOH intake (Panel B) or of
their non-EtOH counterparts (Panel C). A representative picture of the
EtOH and non-EtOH groups in each drug condition is depicted in Panels
E and F, respectively.
Fig. 7. ALDH2 expression in the Nucleus Accumbens (NAc) in basal conditions and after drug administration. Panels A & D: Cell count (A) and re-
presentative pictures (D) in 35-day-old rats. Panels B & E: Cell count (B) and representative pictures (E) in 63-day-old rats which had consumed EtOH.
Panels C & F: Cell count (C) and representative pictures (F) in 63-day-old rats which had not consumed EtOH. The data represent the results of 3–6 animals
per group. PND=postnatal day; EtOH=ethanol; C= control; Pb= lead-exposed; VEH=vehicle; CY= cyanamide.
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3.3.2.1. Effect of age and EtOH intake in brain ALDH2 expression. In the
NAc (Fig. 7A and VEH-bars of panels B and C) the two-way ANOVA
performed for each region separately failed to show a significant effect
of the variables group, age/EtOH or their interaction. However, in the
dStr (Fig. 8A and VEH-bars of panels B and C) a significant effect of the
group variable was evident: F(1,22)= 5.12; p < 0.05; while in the PFC
(Fig. 9A and VEH-bars of panels B and C) a significant difference in the
interaction between group and age/EtOH condition: F(2,22)= 5.08;
p < 0.05 emerged. Thus, the results shown here evidenced a non-
significant reduction in ALDH2 expression in all areas of the adult Pb-
exposed animals compared with the younger animals, independently of
their EtOH consumption history.
3.3.2.2. Effect of drug (VEH or CY) pretreatment on brain ALDH2
expression. The data show that CY administration dramatically
reduced ALDH2 expression in both groups independently of their
EtOH intake, particularly in the NAc, dStr and to a lesser extent in
the PFC. Thus, the three-way ANOVA performed for each area revealed
that in the NAc (Fig. 7B and C), a significant difference was observed in
the variables group: F(1,31)= 6.12; p < 0.05, drug: F(1,31)= 39.70;
p < 0.001 and in the interaction between group x drug: F
(1,31)= 5.26; p < 0.05. In the dStr (Fig. 8B and C) there were
significant differences in the group variable: F(1,31)= 16.09;
p < 0.001, EtOH intake: F(1,31)= 16.60; p < 0.001, and drug: F
(1,31)= 68.06; p < 0.001 variables, and in the interactions group x
drug: F(1,31)= 14.76; p < 0.001, and EtOH intake x drug: F
(1,31)= 10.82; p < 0.01. In the PFC (Fig. 9B and C) a significant
effect of the drug variable: F(1,31)= 10.44; p < 0.01, and of the group
x EtOH intake interaction: F(1,31)= 14.25; p < 0.001 was evident.
Hence, due to the absence of significant differences in the overall
interaction pos hoc analysis was not performed.
4. Discussion
The results presented in this study provide further evidence of CAT
and ALDH2 participation (and brain acetaldehyde accumulation) in the
elevated voluntary EtOH consumption reported by us in male rats
perinatally exposed to Pb.
In relation to CAT expression, we replicate here data reported by
Zimatkin and Lindros (1996) and Moreno et al. (1995), evidencing the
abundance of the enzyme in the brain. Furthermore, we demonstrated
elevated CAT expression in the PFC in the 35-day-old developmentally
Pb-exposed animals, differences that persisted (PFC) or emerged (NAc
and dStr) after EtOH intake. Thus, a significantly higher number of
CAT-positive cells in all areas was evident in the SAL-injected-Pb-ex-
posed animals which had consumed EtOH. This effect was absent when
the respective non-EtOH counterparts were analyzed (with the excep-
tion of the NAc). Interestingly, AT reduced the CAT-positive cells in the
NAc (but neither in the dStr nor in the PFC) in the C animals after EtOH
intake. In contrast, AT administration induced a drastic reduction of
CAT abundance in all areas in the Pb-exposed animals which had
consumed EtOH, although this effect was only present in the NAc of
their non-EtOH counterparts. In contrast, no further increase in the
enzyme expression was observed after 3NPA administration in most
groups, with the exception of the NAc (of both, the C and Pb-exposed
non-EtOH groups) and the PFC (of the Pb-exposed non-EtOH group). On
Fig. 8. ALDH2 expression in the dorsal striatum (dStr) in basal conditions and after drug administration. Panels A & D: Cell count (A) and representative
pictures (D) in 35-day-old rats. Panels B & E: Cell count (B) and representative pictures (E) in 63-day-old rats which had consumed EtOH. Panels C & F: Cell
count (C) and representative pictures (F) in 63-day-old rats which had not consumed EtOH. The data represent the results of 3–6 animals per group.
PND=postnatal day; EtOH= ethanol; C= control; Pb= lead-exposed; VEH=vehicle; CY= cyanamide.
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the basis of these results, we propose that Pb induced a high CAT ac-
tivity (Mattalloni et al., 2013) and expression (this data) that may have
important consequences in the excessive EtOH intake we have reported
in the Pb-exposed rats. Moreover, we have demonstrated that EtOH
intake was reduced in these animals after pharmacological (Mattalloni
et al., 2013 and this data) or molecular (Mattalloni et al., 2019) sup-
pression of CAT activity or expression. In contrast, 3NPA effects were
consistently less robust than those observed with AT. They show a
modest restoration of CAT activity in blood and in the dStr (Mattalloni
et al., 2013), with an increase in CAT expression restricted to the NAc
(C and Pb-exposed rats) and PFC (Pb-exposed animals). These differ-
ences were evident despite the robust increase in EtOH intake observed
in both C and Pb-exposed animals, an effect that may be related to the
indirect mechanism that this drug exerts to increase CAT activity
(Binienda et al., 1998). Thus, although a small portion of the neuronal
and glial population is part of the CAT-positive cells (Zimatkin and
Lindros, 1996; Moreno et al., 1995), it has been demonstrated that
brain CAT activity determines EtOH-derived acetaldehyde production
and the resulting pharmacological effects of this metabolite (Gill et al.,
1992 & 1996, Aragon and Amit, 1985; Quertemont et al., 2005; Israel
et al., 2015).
Regarding ALDH2, we observed low basal expression in the areas
under study, replicating observations of Zimatkin (1991) and Zimatkin
et al. (1992). Interestingly and opposing to CAT, ALDH2 expression
failed to show differences between the 35-day-old C and Pb-exposed
rats. However, Pb exposure selectively decreased ALDH2 expression in
all the three areas under study after EtOH intake. This effect was po-
tentiated by CY administration, a manipulation that further reduced
ALDH2 activity (Mattalloni et al., 2017) and expression (present study)
after EtOH intake in both C and Pb-exposed animals.
One limitation of this study that must be mentioned is the fact that
no gender-related effects were assessed. At this respect, although dif-
ferential toxicokinetic have been reported between male and females in
humans (Ramchandani et al., 2001) and female rats voluntarily drink
more EtOH than their male counterparts, the estrous-cycle had no effect
on alcohol drinking evaluated in several strains and drinking protocols
as reported by Priddy et al. (2017). Regarding the enzymes under study,
neither ALDH nor CAT functionality have been shown to differ across
genders, although some evidences in humans reported that ADH ac-
tivity is higher in the males than in the females (Ramchandani et al.,
2001; Kander et al., 2017).
Another aspect that deserves discussion is the possibility that the 2-
h-limited-access to drinking fluids enhances EtOH toxicokinetic and
elicits a rapid perception of the drug pharmacological effects (Pautassi
et al., 2006). At this respect, we have previously shown that Pb ex-
posure has no effect on EtOH toxicokinetic (Virgolini et al., 1999).
Another consideration is related to the fact that the short period of fluid
availability may promote deprivation stress in these animals. Interest-
ingly, we and others have reported that adult (Haider et al., 2013) or
early-life Pb exposure (Yu et al., 1996; Cory-Slechta et al., 2004;
Virgolini et al., 2004) elevates basal corticosterone levels and triggers a
high reactivity to stressful events compared to their non-exposed
counterparts. Therefore, the possibility that the increased EtOH intake
observed in the Pb-exposed animals was driven by the negative re-
inforcing or anxiolytic effects of the drug requires consideration.
However, this scenario framed in the tension-reduction hypothesis
Fig. 9. ALDH expression in the prefrontal cortex (PFC) in basal conditions and after drug administration. Panels A & D: Cell count (A) and representative
pictures (D) in 35-day-old rats. Panels B & E: Cell count (B) and representative pictures (E) in 63-day-old rats which had consumed EtOH. Panels C & F: Cell
count (C) and representative pictures (F) in 63-day-old rats which had not consumed EtOH. The data represent the results of 3–6 animals per group.
PND=postnatal day; EtOH= ethanol; C= control; Pb= lead-exposed; VEH=vehicle; CY= cyanamide.
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(Pohorecky, 1981) is more likely to occur in later stages of the addiction
process. On the contrary, in the present conditions (initiation and
maintenance of EtOH intake) the positive aspects of reinforcing that are
mediated by the dopaminergic mesocorticolimbic pathway gain prota-
gonism (Gilpin and Koob, 2008; Koob, 2006). In this line, accumulating
evidence suggests that the motivational properties of EtOH are due not
only to its first metabolite acetaldehyde but also to other derivates with
known positive reinforcing properties. This includes the bioproduct
salsolinol (1-methyl-1,2,3,4-tetrahydro-6,7-dihydroxy-isoquinoline),
which results of the condensation of acetaldehyde and dopamine (Deng
and Deitrich, 2008; Xie et al., 2013; Peana et al., 2016). Thereby, the
high CAT and low ALDH2 activity and expression reported in the Pb-
exposed animals after EtOH intake may have profound effects in terms
of acetaldehyde accumulation. This, along with dopamine release
would promote EtOH metabolites and resulting products accumulation
in limbic areas, a scenario potentiated by the elevated EtOH con-
sumption reported in these animals. In conclusion, these results provide
further evidence that support the proposed critical role of acetaldehyde
and related-bioproducts in the vulnerability to initiate an excessive
EtOH intake pattern as a consequence of early-life exposure to Pb, a
neurotoxicant still present ubiquitously in the environment.
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